2121 results about "Genetic testing" patented technology

We describe a method for interrogating the content and primary structure of DNA by microarray analyses and to provide comprehensive genetic screening and diagnostics prior to embryo transfer within an IVF setting. We will accomplish this by the following claims: 1) an optimized embryo grading system, 2) a less invasive embryo biopsy with reduced cellular contamination, 3) an optimized DNA amplification protocol for single cells, 4) identify aneuploidy and structural chromosome abnormalities using microarrays, 5) identifying sub-telomeric chromosome rearrangements, 6) a modified DNA fingerprinting protocol, 7) determine imprinting and epigenetic changes in developing embryos, 8) performing genome-wide scans to clarify/diagnose multi-factorial genetic disease and to determine genotype/haplotype patterns that may predict future disease, 9) determining single gene disorders with or without a known DNA mutation, 10) determining mtDNA mutations and/or the combination of mtDNA and genomic (nuclear) DNA aberrations that cause genetic disease.

A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 90 to 91 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

RNA in sperm can be used as a diagnostic to distinguish between normal and affected individuals. A list of specific diagnostic transcripts is provided which is compared with transcripts obtained from the sperm of a subject. Correlation between the two transcripts is used to identify normal sperm or affected sperm. Addition, genetic testing for male infertility or damage to spermatozoa is accomplished by providing a microarray of DNA probes with a sample of spermatozoa to determine the mRNA fingerprints of the sample, and comparing the mRNA fingerprints of the sample with the mRNA fingerprints of normal fertile male spermatozoa.

A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 70 to 72 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 87 to 89 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

Methods are provided for highly sensitive and rapid in situ detection of a nucleic acid analyte of a known sequence. The method employs oligonucleotide probes in a series of optimized steps to amplify a signal and decrease background. Sensitivity is enhanced such that the method can detect as few as 1–2 copies of nucleic acid analyte per sample, the sample containing a cell, tissue or similar biological material. Methods of detecting and identifying the position of the nucleic acid analyte in a cell are also provided.

Disclosed herein are systems and methods for the assignment of therapeutic pathways to members of a network of oncology. The systems and methods allow for storage of disparate information in a database and determine a uniform semantics for all of the stored information. In addition, the systems and methods allow for the calculation of treatment pathways based on patient information as well as publicly-available information relating to particular diseases, and for the refinement of those treatment pathways as new information is added. Robot-assisted genomic labs permit automated genetic testing, which is integrated with the system.

The invention discloses a gene detection product report system comprising a mobile terminal sales service system which is used for the user to select a gene detection product and place an order to pay and is also used for acquiring basic information of the detected subject and sample binding information; a clinical sample management system which is used for receiving the basic information of the detected subject and the sample binding information from the mobile terminal sales service system; a laboratory data management system which is used for storing samples starting from order placing until the sequencing data are transferred to the specific storage position from a sequencer, wherein a report generation system generates a report to be stored in the laboratory data management system and pushed to the mobile terminal sales service system to be transmitted to the specific report receiver; and the report generation system which is used for receiving the basic information of the detected subject and the sample binding information from the clinical sample management system and the detection result from the laboratory data management system so as to generate the report. Automatic data exchange and centralized report management can be realized, and the report can be automatically generated according to the requirement so as to guarantee the accuracy of the report data.

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells ErbB has been found to be amplified e.g., by fluorescent in situ hybridization. ErbB antagonists described include an anti-HER2 antibody. Pharmaceutical packaging for providing the components for such treatment is also provided.

The invention discloses a gene detection method, a gene detection kit and gene detection equipment. The gene detection method comprises the following steps of arranging a plurality of separation cavities in the kit, blocking the every two adjacent separation cavities by a plunger, and adding a cracking liquid, a cleaning liquid and a reaction liquid into each separation cavity; when a sample is detected, pushing each plunger, aligning a plunger hole of each plunger with the corresponding separation cavity, and further conducting each separation cavity; utilizing an electromagnetic control type to control magnetic beads in the kit to drive the to-be-tested sample to sequentially pass through the separation cavities, and then sequentially cracking, cleaning and reacting; finally, performing optical detection on the gene in the reaction liquid from the exterior.

A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 81 to 83 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.

The invention provides an STAG2 gene mutant sequence and a detection method thereof as well as use of STAG2 gene mutation in detecting bladder cancer and belongs to the technical field of the molecular biology gene detection. The detection method comprises the following steps: (1) extracting a tumor tissue DNA and a peripheral blood DNA from a tumor tissue and the peripheral blood of a bladder cancer patient; (2) performing whole genome sequencing and whole exon sequencing on the two DNAs extracted in the step (1), respectively; (3) performing whole exome sequence alignment and somatic mutation detection on the sequencing results of the step (2), thereby obtaining a mutant gene; (4) verifying the somatic replacement, insertion and deletion of the mutant gene obtained in the step (3) by use of Sanger sequencing; and (5) identifying the mutant gene as the remarkable mutant gene. The detection method has the advantage that the mutation of the STAG2 is one of unfavorable indexes of the bladder cancer and also is capable of serving as a new acting target for treating the bladder cancer.

The invention relates to an anti-pollution portable gene detection method and device. The operation procedure comprises the steps that a PCR pipe containing amplification products is put into a device to conduct sealing, and by means of a series of simple manual operations, a detection result visible by eyes is obtained; target nucleic acid amplification products can be detected rapidly, nucleic acid amplification products can be prevented from being polluted, and a false positive result is avoided. Application can be achieved in the aspects of species identification on the gene level in the fields such as pathogen detection on clinical infectious diseases, food pathogenic microbe detection, agriculture, industry, customs and animal husbandry.

The invention discloses a gene detection report automatic generation method and device; the method comprises the following steps: obtaining heredity information and sample information of a detected object; querying a gene database by using heredity information, and obtaining representation information corresponding to the heredity information; calling a gene detection report standardization template, and introducing the sample information and the representation information corresponding to the heredity information into the standardization template, thus automatically generating the gene detection report. The novel method and device can save mass time, can ensure accuracy, thus timely updating the gene detection report.

A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 92 to 93 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium.